A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

  • End date
    Jun 30, 2024
  • participants needed
  • sponsor
    Peking University Cancer Hospital & Institute
Updated on 4 October 2022
measurable disease
lung adenocarcinoma
endobronchial ultrasound
lung carcinoma


This is a Phase II, single-Arm, prospective study of neoadjuvant Ensartinib for the treatment of patients with ALK positive, resectable for stage II to IIIB(N2) Non-small Cell Lung Cancer

Condition Non Small Cell Lung Cancer
Treatment Ensartinib
Clinical Study IdentifierNCT05380024
SponsorPeking University Cancer Hospital & Institute
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study
Male or female, at least 18 years of age
Histologically or cytologically documented lung adenocarcinoma within 60 days prior to study enrollment
Clinical stage IIA/IIB/IIIA/IIIB assessed by EBUS-TBNA or PET(positron emission tomography)/CT can be resected
Patients confirmed as ALK positive (FISH or Ventana IHC or RT-PCR, NGS)
Presence of at least one accurately measurable lesion, CT showing a maximum diameter of 10mm at baseline (except for lymph nodes with a short axis of 15mm required) and suitable for accurate repeat measurements
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 at enrolment
Hematology , liver and kidney function are adequate for neoadjuvant therapy
Cardiopulmonary function suitable for surgical treatment (ECG, echocardiography, pulmonary function or blood gas analysis)
Serum pregnancy test (for females of childbearing potential) negative at screening.Female patients of non-childbearing potential must meet at least 1 of the following criteria
① Achieved postmenopausal status, defined as follows: cessation of regular
menses forat least 12 consecutive months with no alternative pathological or
physiological cause; status may be confirmed with a serum follicle-
stimulating hormone (FSH)level confirming the postmenopausal state
② Have undergone a documented hysterectomy and/or bilateral oophorectomy
③ Have medically confirmed ovarian failure. All other female patients
(including female patients with tubal ligations) are considered to be of
childbearing potential
Male subjects must be willing to use barrier contraception

Exclusion Criteria

Mixed squamous cell carcinoma, large cell carcinoma,small cell lung cancer
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemotherapy, biologic therapy, immunotherapy, or any investigational drug
Pregnant female patients; breastfeeding female patients
Current use of (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of Cytochrome P450 3A4(CYP3A4)(at least 3 weeks prior)
Evidence of any severe or uncontrolled systemic disease, including uncontrolled hypertension and active bleeding, that the investigator considers to be detrimental to patient participation in the study or to adherence to the protocol. Active and clinically significant bacterial, fungal, or viral infection including hepatitis B virus (HBV) or hepatitis C virus (HCV) (e.g., in case of known HBsAg or HCV antibody positivity), known human immunodeficiency virus (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness
Past medical history of Interstitial lung disease( ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD
A history of hypersensitivity to Icotinib with or without active excipients or to drugs of similar chemical structure or class, and uncontrollable nausea and vomiting, chronic gastrointestinal disease, inability to swallow formulated drugs, or having undergone major bowel resection that would interfere with adequate absorption of Ensartinib
Any of the following cardiac criteria
①Mean resting corrected QT interval (QTc)>470 msec, obtained from 3
electrocardiograms (ECGs)
②Any clinically important abnormalities in rhythm, conduction or morphology of
resting ECG e.g., complete left bundle branch block, third-degree heart block
second-degree heart block, PR interval >250msec, symptomatic bradycardia <45
③Any factors that increase the risk of QTc prolongation or risk of arrhythmic
events such as heart failure, hypokalemia, congenital long QT syndrome, family
history of long QT syndrome or unexplained sudden death under 40 years of age
in first-degree relatives or any concomitant medication known to prolong the
QT interval
A clear past history of neurological or psychiatric disorders, including epilepsy or dementia
Judgment by the investigator that the subject should not participate in the study if the subject is unlikely to comply with study procedures, restrictions and requirements
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note